EMA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7

EMA Grants Orphan Drug Designation to NeoImmuneTech’s NT-I7

By, Admin 5 June 2024

EMA grants orphan drug designation to NeoImmuneTech’s NT-I7 to treat acute radiation syndrome

Overview

NeoImmuneTech, Inc., a clinical-stage T cell-focused biopharmaceutical company, announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation (ODD) to NT-I7 (efineptakin alfa) for the treatment of acute radiation syndrome (ARS).

ODD to NT-I7

  • This regulatory milestone follows the ODD granted to NT-I7 by the FDA in the US for the same indication in November 2023. 
  • It is the second ODD received by NT-I7 from the EMA, following the one granted in Idiopathic CD4+ Lymphocytopenia (ICL) in May 2017.

ARS

  • ARS is a critical condition resulting from a high dose of radiation exposure, causing severe, sometimes fatal damage to the bone marrow and the immune system. 
  • Currently, there are no treatments available that effectively promote T cell recovery after such exposure. 
  • NT-I7, a novel long-acting human interleukin-7 (IL-7), has shown promise to accelerate T cell reconstitution and enhance the immune response, offering a potential solution for this medical unmet need. 
  • Clinical studies have shown that NT-I7 significantly boosts T cell counts, while maintaining a high level of safety and tolerability.

NeoImmuneTech for NT-I7

  • NeoImmuneTech is actively developing NT-I7 in ARS through partnerships with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) and Duke University. 
  • Recently, Duke University secured a $6 million grant from NIAID for NT-I7 development in ARS.
  • Words from CEO: NeoImmuneTech
  • Luke Oh, Ph.D., president and chief executive officer of NeoImmuneTech, said: ""We are thrilled to see the deep interest of the scientific and regulatory community around the potential use of NT-I7 as a medical countermeasure in ARS. 
  • The EMA Orphan Drug Designation marks a new milestone for us, following our recent pre-IND discussions we had with the FDA to accelerate our development programme. It is an important acknowledgment of the potential that NT-I7 holds in providing a beacon of hope for the treatment of ARS.”

About ODD

  • ODD is a status assigned to a medicine intended for use against a rare disease or condition. 
  • The designation provides incentives to advance the development of treatments for rare diseases, including reduced fees for multiple steps in the development process, such as protocol assistance, marketing authorization applications, and inspections before authorization.

NeoImmuneTech

Founded in 2014 and based in Rockville, MD, NeoImmuneTech (NIT) is a clinical-stage T cell-focused biotech company dedicated to the discovery and development of novel immuno-therapeutics.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!